Laura Parisio, Carlo Romano Settanni, Simone Varca, Lucrezia Laterza, Loris Riccardo Lopetuso, Daniele Napolitano, Elisa Schiavoni, Laura Turchini, Caterina Fanali, Norma Alfieri, Marco Pizzoferrato, Alfredo Papa, Pia Clara Pafundi, Alessandro Armuzzi, Antonio Gasbarrini, Daniela Pugliese, Franco Scaldaferri
BACKGROUND AND AIMS: Subcutaneous vedolizumab formulation has been shown to be as effective and safe as the intravenous one in randomized control trials. Real-life data are limited especially for patients receiving long-term intravenous therapy. This study aimed to evaluate the safety and effectiveness of switching from intravenous to subcutaneous vedolizumab in a large cohort of patients with stable clinical remission. METHODS: In this prospective cohort study, we enrolled consecutive patients attending our center between September 2021 and April 2022...
December 22, 2023: Journal of Gastrointestinal and Liver Diseases: JGLD